Consonance Capital

Consonance Capital Management as of Sept. 30, 2018

Portfolio Holdings for Consonance Capital Management

Consonance Capital Management holds 29 positions in its portfolio as reported in the September 2018 quarterly 13F filing

Company (Ticker) Portfolio Weight Valued At Change in Shares Share Count Share Price
Pacira Pharmaceuticals (PCRX) 9.7 $180M 3.7M 49.15
Retrophin 6.0 $113M 3.9M 28.73
United Therapeutics Corporation (UTHR) 5.9 $110M 862k 127.88
Puma Biotechnology (PBYI) 5.7 $106M 2.3M 45.85
Vanda Pharmaceuticals (VNDA) 5.5 $102M 4.4M 22.95
Spectrum Pharmaceuticals 5.3 $98M 5.8M 16.80
Nevro (NVRO) 4.4 $82M 1.4M 57.00
Karyopharm Therapeutics (KPTI) 4.4 $82M 4.8M 17.03
Amarin Corporation (AMRN) 4.3 $81M 5.0M 16.27
NuVasive 4.2 $77M 1.1M 70.98
Myriad Genetics (MYGN) 4.1 $76M 1.6M 46.00
Pacific Biosciences of California (PACB) 3.9 $73M 14M 5.41
Luminex Corporation 3.9 $72M 2.4M 30.31
Urogen Pharma (URGN) 3.9 $72M 1.5M 47.23
Corcept Therapeutics Incorporated (CORT) 3.8 $71M 5.0M 14.02
Exelixis (EXEL) 3.7 $69M 3.9M 17.72
Vericel (VCEL) 3.2 $59M 4.2M 14.15
D Stemline Therapeutics 2.5 $46M 2.7M 16.60
Oxford Immunotec Global 2.1 $40M 2.4M 16.23
Uniqure Nv (QURE) 2.0 $38M 1.0M 36.39
Verastem 2.0 $37M 5.2M 7.25
Savara (SVRA) 1.9 $35M 3.1M 11.16
Adma Biologics (ADMA) 1.5 $28M 4.5M 6.21
Ra Pharmaceuticals 1.4 $26M 1.5M 18.09
Theravance Biopharma (TBPH) 1.3 $24M 732k 32.67
Catalyst Pharmaceutical Partners (CPRX) 1.2 $23M 6.0M 3.78
Sesen Bio 0.9 $16M 7.5M 2.15
Innoviva (INVA) 0.8 $15M 1.0M 15.24
Biosante Pharmaceuticals (ANIP) 0.4 $8.1M 143k 56.54